Literature DB >> 17442774

Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation.

Rupert Handgretinger1, Xiaohua Chen, Matthias Pfeiffer, Ingo Mueller, Tobias Feuchtinger, Gregory A Hale, Peter Lang.   

Abstract

Allogeneic stem cell transplantation is for a number of patients with malignant and nonmalignant diseases the only curative approach. For those patients who do not have an HLA-identical-related or -unrelated stem cell donor, a related three-loci mismatch haploidentical stem cell transplantation with T cell-depleted stem cells is a viable option. T cell depletion either by CD34(+) positive selection or by CD3-negative depletion strategies is available and has been investigated. We have shown that reduced-intensity conditioning haploidentical transplantation using mobilized peripheral stem cells negatively depleted from T and B lymphocytes is associated with a rapid immune reconstitution, a low transplant-related mortality rate, and a favorable outcome in patients in remission at the time of transplant. For chemorefractory patients, additional posttransplant cellular and humoral immunotherapeutic strategies are needed for prevention of relapse after transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442774     DOI: 10.1196/annals.1392.022

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

1.  Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center.

Authors:  G Dufort; L Castillo; S Pisano; M Castiglioni; P Carolina; I Andrea; E Simon; S Zuccolo; M Schelotto; F Morosini; I Pereira; P Amarillo; A Silveira; L Guerrero; V Ferreira; A Tiscornia; R Mezzano; F Lemos; B Boggia; A Quarnetti; J Decaro; A Dabezies
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

2.  Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

3.  KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.

Authors:  Lena Oevermann; Sebastian U Michaelis; Markus Mezger; Peter Lang; Jacek Toporski; Alice Bertaina; Marco Zecca; Lorenzo Moretta; Franco Locatelli; Rupert Handgretinger
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

4.  Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

Review 5.  Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2013-12-24

6.  Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

Authors:  S O Ciurea; R Saliba; G Rondon; S Pesoa; P Cano; M Fernandez-Vina; S Qureshi; L L Worth; J McMannis; P Kebriaei; R B Jones; M Korbling; M Qazilbash; E J Shpall; S Giralt; M de Lima; R E Champlin; J Gajewski
Journal:  Bone Marrow Transplant       Date:  2009-08-10       Impact factor: 5.483

7.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

Review 8.  Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.

Authors:  Saar Gill; Janelle A Olson; Robert S Negrin
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-02       Impact factor: 5.742

Review 9.  Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review.

Authors:  Liang-Piu Koh; Nelson J Chao
Journal:  Blood Cells Mol Dis       Date:  2007-09-19       Impact factor: 3.039

Review 10.  Current status of haploidentical stem cell transplantation for leukemia.

Authors:  Xiao-jun Huang
Journal:  J Hematol Oncol       Date:  2008-12-31       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.